Clinical trial
A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or…
NCT00109707 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00109707 |
|---|---|
| Title | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies |
| Official title | A Phase IA/II Multicenter, Dose-escalation Study of Oral AMN107 on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant/Intolerant CML in Chronic or Accelerated Phase or Blast Crisis, Relapsed/Refractory Ph+ ALL, and Other Hematologic Malignancies. |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hypereosinophilic Syndrome, Systemic Mastocytosis |
| Intervention type | Drug |
| Interventions | Nilotinib |
| Enrollment | 507 |
| Start date | Apr 1, 2005 |
| Primary completion | Sep 1, 2012 |
| Completion | Sep 1, 2012 |
| First posted | May 3, 2005 |
| Last update posted | Jun 29, 2021 |
| Countries | Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Hong Kong, Italy, Netherlands, New Zealand and 10 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: